Skip to content
RaiseKit
VCsFundsInvestmentsStart freePricing
RaiseKit

The most comprehensive database of web3 VCs. Built and maintained by AI agents.

Directory

  • VCs
  • Funds
  • Investments
  • Writing
  • Funding
  • Sectors
  • Geography

Resources

  • RSS Feed
  • Changelog
  • Search
  • Compare VCs
  • Reports
  • Activity
  • Deploying

Subscribe

Weekly digest of VC insights and funding rounds.

Subscribe to digest →

© 2026 RaiseKit. Data updated nightly by AI agents.

PrivacyTermsSupportDelete accountRSS
  1. Sectors
  2. /Healthcare AI

Healthcare AI

10 VCs and 0 funds investing in Healthcare AI

VCs investing in Healthcare AI

Nadia Cochinwala

Principal

88%

Kleiner Perkins

Check: No personal check range or signing authority is published. Nadia's current portfolio includes early and growth investments; individual company round sizes are not a personal range.

Nadia invests across enterprise applications and infrastructure, from AI compute and networking to vertical AI in healthcare, finance, sales, coding, and productivity. Her official portfolio spans both early and growth stages and emphasizes systems that meet domain-specific standards—clinical evidence, financial auditability, low-latency media, safe autonomy, or enterprise context—rather than generic AI capability alone.

SeedSeries AEarly Stage

Michael Robinson

Partner, Head of Investment Team

87%

Craft Ventures

Check: No personal check-size range is published. Craft invests from early-stage venture through growth, and Michael's disclosed financings span several stages; those total round sizes are not personal or standard check sizes.

Michael invests across venture and growth with a focus on cybersecurity, infrastructure, and AI applications. His operating framework prizes durable revenue, efficient growth, healthy unit economics, precise ideal-customer selection, strong retention, and repeatable go-to-market systems. His recent portfolio work concentrates on autonomous security, machine and agent identity, developer platforms, data infrastructure, and applied AI with clear production usage.

Series ASeries BSeries C

Christian zu Jeddeloh

Former Investment Manager

85%

Norrsken Impact Fund

Check: Historical Norrsken role. The firm now publishes €1M–€10M tickets, but no personal ticket or present investing authority should be inferred because Christian left for an operating role in 2026.

During his Norrsken tenure, Christian explored frontier technologies where difficult physical environments create enabling infrastructure for Earth: satellites for climate intelligence, microgravity for drugs, semiconductors and materials, and in-space supply chains. His move to Biorce shifts his current work from capital allocation to operating an AI clinical-trial platform.

Historical: SeedHistorical: Series APortfolio Operations

Yousef Albabtain

Partner

85%

Shorooq Partners

Check: No personal check range is published. Shorooq invests regionally from idea/pre-seed through late-stage growth via different vehicles. Founders should identify the stage-appropriate fund and not infer a check size from Yousef's Partner title or from announced company rounds.

Yousef backs technology businesses that can become durable leaders in Saudi Arabia and the wider MENA region. His public portfolio and Intelmatix commentary point to a value-investor lens: strong founders, defensible technology, a locally important problem, evidence of commercial demand, and the capacity to unlock productivity or access in sectors such as fintech, enterprise AI, retail, logistics and real estate.

Pre-SeedSeedEarly Stage

Kindle Van Linge

Principal

83%

Craft Ventures

Check: No Kindle-specific check range is public. Craft's live portfolio attributes her to growth, Series A and Series B investments, but those stage labels do not reveal individual allocation authority or check size. Confirm current vehicle, ownership and lead/co-invest posture directly.

Kindle invests where AI or advanced technology becomes a mission-critical operating layer in large, regulated or technically demanding markets. Her attributed work spans AI medical knowledge, regulatory compliance, autonomous defense systems, biotechnology and neurotechnology, with a recurring emphasis on trusted domain data, expert workflows, demonstrable adoption and products capable of becoming the intelligence layer for an industry.

Series ASeries BGrowth

Josh Coyne

Partner

81%

Kleiner Perkins

Check: Not publicly disclosed. Kleiner Perkins invests from early stage through selective growth rounds; isolated portfolio check disclosures should not be treated as Josh's standard range.

Josh backs founders applying AI to consequential workflows in both software and the physical economy. His portfolio shows a consistent preference for products that turn abundant but fragmented information into trustworthy decisions or actions, automate labor-constrained expert work, or combine software with hardware to reverse structural productivity declines. He remains open beyond named sectors when a founder is determined to reinvent an industry.

SeedSeries AEarly Stage

Roy Rosin

Board Partner

80%

First Round Capital

Check: Firm-level: First Round says initial investments typically range from $1M-$7M, average about $3.5M, and have ranged below and above that; participating rounds have ranged from $100K-$20M.

Roy spends most of his First Round time in healthcare, applying three decades of product, innovation, and care-delivery experience to companies that can materially improve lives. He favors practical experimentation and measurable implementation over technology theater: identify a consequential workflow, build with the private context and orchestration required for accuracy, rigorously test real outcomes, and help founders win early customers, prioritize development, refine sales, hire, and learn faster.

Pre-SeedSeed

Dan Moor

Principal

80%

Craft Ventures

Check: No Dan-specific check range is public. Craft invests across early and growth stages through separate venture and growth funds; Dan's official profile emphasizes helping early-stage founders, while recent attributed investments range from Seed through later-stage rounds. Confirm current vehicle and sizing through inquiries@craftventures.com.

Dan backs early-stage B2B and vertical software, cybersecurity, infrastructure and physical-AI companies where a strong product insight can become a scalable operating and go-to-market machine. His investing lens is unusually operator-led: he underwrites customer pain and technical differentiation, then tests whether the team can segment its market, allocate capital rigorously, build repeatable distribution and move from early traction to predictable growth.

SeedSeries ASeries B

Adina Tecklu

Partner

80%

Khosla Ventures

Check: No current personal check range is published. Khosla's Seed Fund backs experiments and may invest alone or with angels/smaller funds; Samir Kaul described historical seed investments as roughly $1M–$2M in 2020. The Main Fund covers early through later-stage financings, including total rounds above $10M. These are firm-level guideposts, not Adina's personal authority.

Adina backs exceptional founders before market consensus and works with them from product-market fit through breakout growth. Her stated focus is early-stage software, AI, and fintech, with disclosed investments spanning home-equity credit, AI-native accounting and legal/software creation, stablecoin payments, receivables automation, AI security, and mental-health AI. Her operating lens begins with the customer and connects product strategy to go-to-market execution.

Pre-SeedSeedSeries A

Kindle Van Linge

Principal

78%

Craft Ventures

Check: No personal check-size range is published. Her disclosed Craft work spans venture and growth investments, including Series A, Series B, and growth-stage companies; public financing totals are not her individual allocation authority.

Kindle invests in technically differentiated AI, defense, and enterprise software that turns expert knowledge or hard engineering into a high-trust operational system. Her published cases favor products that automate expensive, consequential workflows while improving quality: regulatory agents that encode rules, medical intelligence grounded in evidence, and autonomous or frontier systems with strategic importance. Her growth background adds attention to adoption, category position, and scalable economics.

Series ASeries BGrowth